Paclitaxel and gemcitabine ( PG ) combination chemotherapy is effective as a maintenance chemotherapeutic regimen in metastatic breast cancer ( MBC ) patients because it increases progression-free survival ( PFS ) , which increases overall survival ( OS ) .